Matches in Wikidata for { <http://www.wikidata.org/entity/Q92119609> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- Q92119609 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q92119609 description "scientific article published on 21 April 2020" @default.
- Q92119609 description "wetenschappelijk artikel" @default.
- Q92119609 description "наукова стаття, опублікована 21 квітня 2020" @default.
- Q92119609 description "գիտական հոդված հրատարակված 2020 թվականի ապրիլի 21-ին" @default.
- Q92119609 name "Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)" @default.
- Q92119609 name "Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)" @default.
- Q92119609 type Item @default.
- Q92119609 label "Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)" @default.
- Q92119609 label "Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)" @default.
- Q92119609 prefLabel "Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)" @default.
- Q92119609 prefLabel "Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)" @default.
- Q92119609 P1433 Q92119609-941989E3-E047-4907-BFFA-759317C0B206 @default.
- Q92119609 P1476 Q92119609-024C4C6B-9C00-45C6-8598-E7A380BDCEBC @default.
- Q92119609 P2093 Q92119609-27DB2217-D799-484E-A236-02E38D6881DB @default.
- Q92119609 P2093 Q92119609-32B57A07-44B0-4724-A308-0EF267044F5F @default.
- Q92119609 P2093 Q92119609-3BCD2BC3-01CF-4CAA-ACF4-96A130720071 @default.
- Q92119609 P2093 Q92119609-3EE05B69-D029-4808-AB7C-EF79103600C0 @default.
- Q92119609 P2093 Q92119609-41267A53-270B-422F-9C2D-C9AE66B8999D @default.
- Q92119609 P2093 Q92119609-4F0B77D2-7745-46BC-88B1-01F90E5E80C6 @default.
- Q92119609 P2093 Q92119609-6CDCE2E2-B60C-44EB-9CB8-B359FEAF9315 @default.
- Q92119609 P2093 Q92119609-7680B8E0-8619-496B-8EEA-5C9D488BB399 @default.
- Q92119609 P2093 Q92119609-787BAB4B-8109-4BE1-B929-21486ECB814E @default.
- Q92119609 P2093 Q92119609-7B439943-3A80-4DDE-A223-D537F25E80E4 @default.
- Q92119609 P2093 Q92119609-9A759989-D1F6-486F-9B8A-52E819674F40 @default.
- Q92119609 P2093 Q92119609-BF644DAC-B404-47AD-A82B-AA7C5B377C3A @default.
- Q92119609 P2093 Q92119609-C01AD78D-0F29-400A-9D9D-9A1332E2F68E @default.
- Q92119609 P2093 Q92119609-E51A7EDA-F63E-42D4-8064-2634BA24A889 @default.
- Q92119609 P2093 Q92119609-F2A419CB-C727-400D-BCE6-36DCD59C833F @default.
- Q92119609 P2093 Q92119609-F4E4B6D7-396D-4437-A48C-30E4DF02C3B2 @default.
- Q92119609 P31 Q92119609-DCFE341C-E98D-474E-B5EC-5D168A1B0F3A @default.
- Q92119609 P356 Q92119609-AB26FC3C-8AF8-4A9F-8446-F5762C0C4A71 @default.
- Q92119609 P577 Q92119609-68DB8FCA-A88C-4406-BDC9-E854FB6658D8 @default.
- Q92119609 P698 Q92119609-6DA53C6D-4657-48C4-BD74-BCB962903C69 @default.
- Q92119609 P921 Q92119609-30C87F32-C2DB-4D37-8E29-5D8B79CF75E1 @default.
- Q92119609 P921 Q92119609-C849819D-0300-4541-B984-AB6AE946DE4B @default.
- Q92119609 P932 Q92119609-4E4FF809-304D-4517-8420-5E8F9F1D043C @default.
- Q92119609 P356 BJD.19147 @default.
- Q92119609 P698 32316070 @default.
- Q92119609 P1433 Q4970191 @default.
- Q92119609 P1476 "Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)" @default.
- Q92119609 P2093 "A Pinter" @default.
- Q92119609 P2093 "A S Paller" @default.
- Q92119609 P2093 "C A Little" @default.
- Q92119609 P2093 "C R Capriles" @default.
- Q92119609 P2093 "E Edson-Heredia" @default.
- Q92119609 P2093 "G A Magariños" @default.
- Q92119609 P2093 "G Gallo" @default.
- Q92119609 P2093 "IXORA-PEDS study group" @default.
- Q92119609 P2093 "J Bagel" @default.
- Q92119609 P2093 "J Cather" @default.
- Q92119609 P2093 "K Papp" @default.
- Q92119609 P2093 "L Li" @default.
- Q92119609 P2093 "M M B Seyger" @default.
- Q92119609 P2093 "R G Lima" @default.
- Q92119609 P2093 "S Keller" @default.
- Q92119609 P2093 "W Xu" @default.
- Q92119609 P31 Q13442814 @default.
- Q92119609 P356 "10.1111/BJD.19147" @default.
- Q92119609 P577 "2020-04-21T00:00:00Z" @default.
- Q92119609 P698 "32316070" @default.
- Q92119609 P921 Q10355321 @default.
- Q92119609 P921 Q269829 @default.
- Q92119609 P932 "7496501" @default.